Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) announced its quarterly earnings data on Friday. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.22 by $0.01, FiscalAI reports. The company had revenue of $83.70 million for the quarter, compared to the consensus estimate of $83.61 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%.
Aurinia Pharmaceuticals Price Performance
AUPH stock traded down $0.55 during trading on Friday, hitting $16.66. The stock had a trading volume of 600,545 shares, compared to its average volume of 1,147,126. The company’s 50-day moving average price is $16.50 and its two-hundred day moving average price is $15.64. Aurinia Pharmaceuticals has a twelve month low of $12.07 and a twelve month high of $19.25. The stock has a market capitalization of $2.22 billion, a P/E ratio of 7.28 and a beta of 1.60. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97.
Analysts Set New Price Targets
AUPH has been the subject of a number of analyst reports. Royal Bank Of Canada increased their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Weiss Ratings raised Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 22nd. Bloom Burton upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $17.75.
Read Our Latest Report on AUPH
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.
Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.
Featured Articles
- Five stocks we like better than Aurinia Pharmaceuticals
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
